Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 279

1.

Analgesic Effects of Hydromorphone versus Buprenorphine in Buprenorphine-maintained Individuals.

Huhn AS, Strain EC, Bigelow GE, Smith MT, Edwards RR, Tompkins DA.

Anesthesiology. 2019 Jan;130(1):131-141. doi: 10.1097/ALN.0000000000002492.

PMID:
30418214
2.

Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes.

Dunn KE, Weerts EM, Huhn AS, Schroeder JR, Tompkins DA, Bigelow GE, Strain EC.

Addict Biol. 2018 Oct 8. doi: 10.1111/adb.12680. [Epub ahead of print]

PMID:
30295400
3.

Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia.

Oh ES, Blennow K, Bigelow GE, Inouye SK, Marcantonio ER, Neufeld KJ, Rosenberg PB, Troncoso JC, Wang NY, Zetterberg H, Sieber FE, Lyketsos CG.

PLoS One. 2018 Sep 25;13(9):e0204695. doi: 10.1371/journal.pone.0204695. eCollection 2018. Erratum in: PLoS One. 2018 Oct 26;13(10):e0206719.

4.

Effect of Depth of Sedation in Older Patients Undergoing Hip Fracture Repair on Postoperative Delirium: The STRIDE Randomized Clinical Trial.

Sieber FE, Neufeld KJ, Gottschalk A, Bigelow GE, Oh ES, Rosenberg PB, Mears SC, Stewart KJ, Ouanes JP, Jaberi M, Hasenboehler EA, Li T, Wang NY.

JAMA Surg. 2018 Nov 1;153(11):987-995. doi: 10.1001/jamasurg.2018.2602.

PMID:
30090923
5.

Naloxone formulation for overdose reversal preference among patients receiving opioids for pain management.

Dunn KE, Barrett FS, Bigelow GE.

Addict Behav. 2018 Nov;86:56-60. doi: 10.1016/j.addbeh.2018.03.011. Epub 2018 Mar 28.

PMID:
29625751
6.

Extended-release injectable naltrexone for opioid use disorder: a systematic review.

Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, Silverman K.

Addiction. 2018 Jul;113(7):1188-1209. doi: 10.1111/add.14180. Epub 2018 Mar 24. Review.

PMID:
29396985
7.

Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults.

Schlienz NJ, Cone EJ, Herrmann ES, Lembeck NA, Mitchell JM, Bigelow GE, Flegel R, LoDico CP, Hayes ED, Vandrey R.

J Anal Toxicol. 2018 May 1;42(4):232-247. doi: 10.1093/jat/bkx102.

PMID:
29300962
8.

Characterizing the subjective, observer-rated, and physiological effects of hydromorphone relative to heroin in a human laboratory study.

Dunn KE, Brands B, Marsh DC, Bigelow GE.

Psychopharmacology (Berl). 2018 Apr;235(4):971-981. doi: 10.1007/s00213-017-4814-3. Epub 2017 Dec 21.

PMID:
29270641
9.

Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.

Dunn KE, Tompkins DA, Bigelow GE, Strain EC.

JAMA Psychiatry. 2017 Sep 1;74(9):885-893. doi: 10.1001/jamapsychiatry.2017.1838.

10.

An intensive assessment of alcohol use and emergency department utilization in homeless alcohol-dependent adults.

Holtyn AF, Jarvis BP, Subramaniam S, Wong CJ, Fingerhood M, Bigelow GE, Silverman K.

Drug Alcohol Depend. 2017 Sep 1;178:28-31. doi: 10.1016/j.drugalcdep.2017.04.025. Epub 2017 Jun 10.

11.

Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.

Jarvis BP, Holtyn AF, Berry MS, Subramaniam S, Umbricht A, Fingerhood M, Bigelow GE, Silverman K.

J Subst Abuse Treat. 2018 Feb;85:38-44. doi: 10.1016/j.jsat.2017.04.012. Epub 2017 Apr 20.

PMID:
28449955
12.

Randomized controlled trial of a computerized opioid overdose education intervention.

Dunn KE, Yepez-Laubach C, Nuzzo PA, Fingerhood M, Kelly A, Berman S, Bigelow GE.

Drug Alcohol Depend. 2017 Apr 1;173 Suppl 1:S39-S47. doi: 10.1016/j.drugalcdep.2016.12.003.

13.

Prescription opioids: New perspectives and research on their role in chronic pain management and addiction.

Stitzer ML, Schwartz RP, Bigelow GE.

Drug Alcohol Depend. 2017 Apr 1;173 Suppl 1:S1-S3. doi: 10.1016/j.drugalcdep.2016.11.018. No abstract available.

14.

Factors associated with using opiates while under extended-release naltrexone blockade: A descriptive pilot study.

Jarvis BP, DeFulio A, Long L, Holtyn AF, Umbricht A, Fingerhood M, Bigelow GE, Silverman K.

J Subst Abuse Treat. 2018 Feb;85:56-60. doi: 10.1016/j.jsat.2016.12.006. Epub 2016 Dec 24.

PMID:
28161142
15.

Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes.

Vandrey R, Herrmann ES, Mitchell JM, Bigelow GE, Flegel R, LoDico C, Cone EJ.

J Anal Toxicol. 2017 Mar 1;41(2):83-99. doi: 10.1093/jat/bkx012.

16.

Effects of incentives for naltrexone adherence on opiate abstinence in heroin-dependent adults.

Jarvis BP, Holtyn AF, DeFulio A, Dunn KE, Everly JJ, Leoutsakos JS, Umbricht A, Fingerhood M, Bigelow GE, Silverman K.

Addiction. 2017 May;112(5):830-837. doi: 10.1111/add.13724. Epub 2017 Feb 3.

17.

Opioid Overdose Experience, Risk Behaviors, and Knowledge in Drug Users from a Rural versus an Urban Setting.

Dunn KE, Barrett FS, Yepez-Laubach C, Meyer AC, Hruska BJ, Petrush K, Berman S, Sigmon SC, Fingerhood M, Bigelow GE.

J Subst Abuse Treat. 2016 Dec;71:1-7.

18.

Opioid Overdose History, Risk Behaviors, and Knowledge in Patients Taking Prescribed Opioids for Chronic Pain.

Dunn KE, Barrett FS, Fingerhood M, Bigelow GE.

Pain Med. 2017 Aug 1;18(8):1505-1515. doi: 10.1093/pm/pnw228.

19.

Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.

Sigmon SC, Bigelow GE.

Addiction. 2017 Mar;112(3):386-387. doi: 10.1111/add.13539. Epub 2016 Aug 26. No abstract available.

PMID:
27561982
20.

Brief Opioid Overdose Knowledge (BOOK): A Questionnaire to Assess Overdose Knowledge in Individuals Who Use Illicit or Prescribed Opioids.

Dunn KE, Barrett FS, Yepez-Laubach C, Meyer AC, Hruska BJ, Sigmon SC, Fingerhood M, Bigelow GE.

J Addict Med. 2016 Sep-Oct;10(5):314-23. doi: 10.1097/ADM.0000000000000235.

21.

Nonsmoker Exposure to Secondhand Cannabis Smoke. III. Oral Fluid and Blood Drug Concentrations and Corresponding Subjective Effects.

Cone EJ, Bigelow GE, Herrmann ES, Mitchell JM, LoDico C, Flegel R, Vandrey R.

J Anal Toxicol. 2015 Sep;39(7):497-509. doi: 10.1093/jat/bkv070. Epub 2015 Jul 2.

22.

Non-smoker exposure to secondhand cannabis smoke II: Effect of room ventilation on the physiological, subjective, and behavioral/cognitive effects.

Herrmann ES, Cone EJ, Mitchell JM, Bigelow GE, LoDico C, Flegel R, Vandrey R.

Drug Alcohol Depend. 2015 Jun 1;151:194-202. doi: 10.1016/j.drugalcdep.2015.03.019. Epub 2015 Apr 6.

23.

Effects of methadone plus alcohol on cognitive performance in methadone-maintained volunteers.

Kleykamp BA, Vandrey RG, Bigelow GE, Strain EC, Mintzer MZ.

Am J Drug Alcohol Abuse. 2015 May;41(3):251-6. doi: 10.3109/00952990.2014.987348. Epub 2015 Jan 13.

24.

Topiramate impairs cognitive function in methadone-maintained individuals with concurrent cocaine dependence.

Rass O, Umbricht A, Bigelow GE, Strain EC, Johnson MW, Mintzer MZ.

Psychol Addict Behav. 2015 Mar;29(1):237-46. doi: 10.1037/adb0000027. Epub 2014 Nov 3.

25.

Non-smoker exposure to secondhand cannabis smoke. I. Urine screening and confirmation results.

Cone EJ, Bigelow GE, Herrmann ES, Mitchell JM, LoDico C, Flegel R, Vandrey R.

J Anal Toxicol. 2015 Jan-Feb;39(1):1-12. doi: 10.1093/jat/bku116. Epub 2014 Oct 17.

26.

Employment-based reinforcement of adherence to oral naltrexone in unemployed injection drug users: 12-month outcomes.

Dunn K, DeFulio A, Everly JJ, Donlin WD, Aklin WM, Nuzzo PA, Leoutsakos JM, Umbricht A, Fingerhood M, Bigelow GE, Silverman K.

Psychol Addict Behav. 2015 Jun;29(2):270-6. doi: 10.1037/adb0000010. Epub 2014 Aug 18.

27.

A therapeutic workplace for the long-term treatment of drug addiction and unemployment: eight-year outcomes of a social business intervention.

Aklin WM, Wong CJ, Hampton J, Svikis DS, Stitzer ML, Bigelow GE, Silverman K.

J Subst Abuse Treat. 2014 Nov-Dec;47(5):329-38. doi: 10.1016/j.jsat.2014.06.013. Epub 2014 Jul 12.

28.

Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial.

Umbricht A, DeFulio A, Winstanley EL, Tompkins DA, Peirce J, Mintzer MZ, Strain EC, Bigelow GE.

Drug Alcohol Depend. 2014 Jul 1;140:92-100. doi: 10.1016/j.drugalcdep.2014.03.033. Epub 2014 Apr 16.

29.

Cognitive performance in methadone maintenance patients: effects of time relative to dosing and maintenance dose level.

Rass O, Kleykamp BA, Vandrey RG, Bigelow GE, Leoutsakos JM, Stitzer ML, Strain EC, Copersino ML, Mintzer MZ.

Exp Clin Psychopharmacol. 2014 Jun;22(3):248-256. doi: 10.1037/a0035712. Epub 2014 Feb 17.

30.

Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations.

O'Connor AB, Turk DC, Dworkin RH, Katz NP, Colucci R, Haythornthwaite JA, Klein M, O'Brien C, Posner K, Rappaport BA, Reisfield G, Adams EH, Balster RL, Bigelow GE, Burke LB, Comer SD, Cone E, Cowan P, Denisco RA, Farrar JT, Foltin RW, Haddox JD, Hertz S, Jay GW, Junor R, Kopecky EA, Leiderman DB, McDermott MP, Palmer PP, Raja SN, Rauschkolb C, Rowbotham MC, Sampaio C, Setnik B, Smith SM, Sokolowska M, Stauffer JW, Walsh SL, Zacny JP.

Pain. 2013 Nov;154(11):2324-34. doi: 10.1016/j.pain.2013.06.035. Review.

PMID:
24148704
31.

Monetary incentives to reinforce engagement and achievement in a job-skills training program for homeless, unemployed adults.

Koffarnus MN, Wong CJ, Fingerhood M, Svikis DS, Bigelow GE, Silverman K.

J Appl Behav Anal. 2013 Fall;46(3):582-91. doi: 10.1002/jaba.60. Epub 2013 Aug 12.

32.

The effect of repeated intramuscular alfentanil injections on experimental pain and abuse liability indices in healthy males.

Tompkins DA, Smith MT, Bigelow GE, Moaddel R, Venkata SL, Strain EC.

Clin J Pain. 2014 Jan;30(1):36-45. doi: 10.1097/AJP.0b013e3182851758.

33.

Opioid abusers' ability to differentiate an opioid from placebo in laboratory challenge testing.

Antoine DG, Strain EC, Tompkins DA, Bigelow GE.

Drug Alcohol Depend. 2013 Sep 1;132(1-2):369-72. doi: 10.1016/j.drugalcdep.2013.01.001. Epub 2013 Jan 28.

34.

Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users.

Dunn KE, Defulio A, Everly JJ, Donlin WD, Aklin WM, Nuzzo PA, Leoutsakos JM, Umbricht A, Fingerhood M, Bigelow GE, Silverman K.

Exp Clin Psychopharmacol. 2013 Feb;21(1):74-83. doi: 10.1037/a0030743. Epub 2012 Dec 3.

35.

Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations.

Comer SD, Zacny JP, Dworkin RH, Turk DC, Bigelow GE, Foltin RW, Jasinski DR, Sellers EM, Adams EH, Balster R, Burke LB, Cerny I, Colucci RD, Cone E, Cowan P, Farrar JT, Haddox JD, Haythornthwaite JA, Hertz S, Jay GW, Johanson CE, Junor R, Katz NP, Klein M, Kopecky EA, Leiderman DB, McDermott MP, O'Brien C, O'Connor AB, Palmer PP, Raja SN, Rappaport BA, Rauschkolb C, Rowbotham MC, Sampaio C, Setnik B, Sokolowska M, Stauffer JW, Walsh SL.

Pain. 2012 Dec;153(12):2315-24. doi: 10.1016/j.pain.2012.07.035. Epub 2012 Sep 19.

36.

Risk-taking propensity as a predictor of induction onto naltrexone treatment for opioid dependence.

Aklin WM, Severtson SG, Umbricht A, Fingerhood M, Bigelow GE, Lejuez CW, Silverman K.

J Clin Psychiatry. 2012 Aug;73(8):e1056-61. doi: 10.4088/JCP.09m05807.

37.

Comparison of cognitive performance in methadone maintenance patients with and without current cocaine dependence.

Henry PK, Umbricht A, Kleykamp BA, Vandrey R, Strain EC, Bigelow GE, Mintzer MZ.

Drug Alcohol Depend. 2012 Jul 1;124(1-2):167-71. doi: 10.1016/j.drugalcdep.2011.12.009. Epub 2012 Jan 21.

38.

Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course.

Bigelow GE, Preston KL, Schmittner J, Dong Q, Gastfriend DR.

Drug Alcohol Depend. 2012 Jun 1;123(1-3):57-65. doi: 10.1016/j.drugalcdep.2011.10.018. Epub 2011 Nov 12.

39.

Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial.

DeFulio A, Everly JJ, Leoutsakos JM, Umbricht A, Fingerhood M, Bigelow GE, Silverman K.

Drug Alcohol Depend. 2012 Jan 1;120(1-3):48-54. doi: 10.1016/j.drugalcdep.2011.06.023. Epub 2011 Jul 22.

40.

Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials.

Donovan DM, Bigelow GE, Brigham GS, Carroll KM, Cohen AJ, Gardin JG, Hamilton JA, Huestis MA, Hughes JR, Lindblad R, Marlatt GA, Preston KL, Selzer JA, Somoza EC, Wakim PG, Wells EA.

Addiction. 2012 Apr;107(4):694-708. doi: 10.1111/j.1360-0443.2011.03473.x. Epub 2011 Jul 22.

41.

A randomized clinical trial of a Therapeutic Workplace for chronically unemployed, homeless, alcohol-dependent adults.

Koffarnus MN, Wong CJ, Diemer K, Needham M, Hampton J, Fingerhood M, Svikis DS, Bigelow GE, Silverman K.

Alcohol Alcohol. 2011 Sep-Oct;46(5):561-9. doi: 10.1093/alcalc/agr057. Epub 2011 May 27.

42.

Discriminative stimulus effects of tramadol in humans.

Duke AN, Bigelow GE, Lanier RK, Strain EC.

J Pharmacol Exp Ther. 2011 Jul;338(1):255-62. doi: 10.1124/jpet.111.181131. Epub 2011 Apr 5.

43.

Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial.

Everly JJ, DeFulio A, Koffarnus MN, Leoutsakos JM, Donlin WD, Aklin WM, Umbricht A, Fingerhood M, Bigelow GE, Silverman K.

Addiction. 2011 Jul;106(7):1309-18. doi: 10.1111/j.1360-0443.2011.03400.x. Epub 2011 May 3.

44.

Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.

Strain EC, Harrison JA, Bigelow GE.

Clin Pharmacol Ther. 2011 Mar;89(3):443-9. doi: 10.1038/clpt.2010.352. Epub 2011 Jan 26.

45.

A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients.

Winstanley EL, Bigelow GE, Silverman K, Johnson RE, Strain EC.

J Subst Abuse Treat. 2011 Apr;40(3):255-64. doi: 10.1016/j.jsat.2010.11.010. Epub 2011 Jan 26.

46.

Physical dependence potential of daily tramadol dosing in humans.

Lanier RK, Lofwall MR, Mintzer MZ, Bigelow GE, Strain EC.

Psychopharmacology (Berl). 2010 Sep;211(4):457-66. doi: 10.1007/s00213-010-1919-3. Epub 2010 Jun 30.

47.

Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers.

Duke AN, Correia CJ, Walsh SL, Bigelow GE, Strain EC.

Psychopharmacology (Berl). 2010 Aug;211(3):303-12. doi: 10.1007/s00213-010-1898-4. Epub 2010 Jun 25.

48.

Effects of repeated tramadol and morphine administration on psychomotor and cognitive performance in opioid-dependent volunteers.

Mintzer MZ, Lanier RK, Lofwall MR, Bigelow GE, Strain EC.

Drug Alcohol Depend. 2010 Oct 1;111(3):265-8. doi: 10.1016/j.drugalcdep.2010.05.002. Epub 2010 Jun 9.

49.

Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone.

Tompkins DA, Lanier RK, Harrison JA, Strain EC, Bigelow GE.

Psychopharmacology (Berl). 2010 Jul;210(4):471-80. doi: 10.1007/s00213-010-1838-3. Epub 2010 Apr 13.

50.

Measurement of self-reported HIV risk behaviors in injection drug users: comparison of standard versus timeline follow-back administration procedures.

Copersino ML, Meade CS, Bigelow GE, Brooner RK.

J Subst Abuse Treat. 2010 Jan;38(1):60-5. doi: 10.1016/j.jsat.2009.06.004. Epub 2009 Aug 29.

Supplemental Content

Loading ...
Support Center